BRIEF-Organon Announces US FDA Approval Of Supplemental New Drug Application Extending Duration Of Use Of Nexplanon® 68 Mg Radiopaque

Reuters
01/17
BRIEF-Organon Announces US FDA Approval Of Supplemental New Drug Application Extending Duration Of Use Of Nexplanon® 68 Mg Radiopaque

Jan 16 (Reuters) - Organon & Co OGN.N:

  • ORGANON ANNOUNCES US FOOD AND DRUG ADMINISTRATION APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION EXTENDING DURATION OF USE OF NEXPLANON® (ETONOGESTREL IMPLANT) 68 MG RADIOPAQUE

  • ORGANON & CO - NEXPLANON USE EXTENDED TO FIVE YEARS

Source text: ID:nBw6MtY47a

Further company coverage: OGN.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10